Description
An inhibitor of HDAC1-3 and KDM1A; reduces cell viability in a panel of CRC cell lines at 1-10 µM and in patient-derived CRC cell lines at 5 µM; induces cell cycle arrest at the G2/M phase in HT-29 cells and primary human CRC cells at 5 µM; increases apoptosis in HT-29 cells in a concentration-dependent manner, an effect that is enhanced by the Akt inhibitors perifosine and MK-2206; reduces tumor growth in an HT-29 mouse xenograft model at 100 mg/kg, p.o., every other day when administered alone and to an enhanced degree when co-administered with oxaliplatin
Formal name: (2E)-N-(2-aminophenyl)-3-[1-[[4-(1-methyl-1H-pyrazol-4-yl)phenyl]sulfonyl]-1H-pyrrol-3-yl]-2-propenamide, 4-methylbenzenesulfonate
Synonyms:
Molecular weight: 619.7
CAS: 1186222-89-8
Purity: ≥98%
Formulation: A solid
Product Type|Biochemicals|Small Molecule Inhibitors|Deacetylases||Research Area|Cancer|Cell Cycle|G2/M||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Epigenetics, Transcription, & Translation|Erasers|Histone Deacetylation||Research Area|Epigenetics, Transcription, & Translation|Erasers|Histone Demethylation
